Compare CNTX & FMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CNTX | FMY |
|---|---|---|
| Founded | 2015 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.7M | 47.0M |
| IPO Year | 2021 | 2005 |
| Metric | CNTX | FMY |
|---|---|---|
| Price | $0.16 | $10.98 |
| Analyst Decision | Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $3.79 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 4.6K |
| Earning Date | 11-10-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.98% |
| EPS Growth | ★ 17.39 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.15 | $10.67 |
| 52 Week High | $3.62 | $12.36 |
| Indicator | CNTX | FMY |
|---|---|---|
| Relative Strength Index (RSI) | 32.26 | 41.73 |
| Support Level | N/A | $10.73 |
| Resistance Level | $0.22 | $11.52 |
| Average True Range (ATR) | 0.02 | 0.20 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 12.13 | 7.41 |
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
First Trust Mortgage Income Fund is a United States-based diversified, closed-end management investment company. The fund's primary investment objective is to seek a high level of current income. Its secondary investment objective is to preserve capital. The fund pursues its objectives by investing predominantly in mortgage-backed securities representing part ownership in a pool of either residential or commercial mortgage loans that, in the opinion of the Fund's investment advisor, offer an attractive combination of credit quality, yield, and maturity.